<DOC>
	<DOC>NCT01720901</DOC>
	<brief_summary>To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients who progressed after gefitinib therapy.</brief_summary>
	<brief_title>Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy</brief_title>
	<detailed_description>This single center, single arm open label study is designed to assess the safety and efficacy of using high dose of Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that progressed after routine gefitinib therapy by progression-free survival, as well as overall survival and disease control rate. The adverse events and adverse reaction are evaluated as well.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed local advanced or metastatic stage IIIB/IV NSCLC. Have been treated with gefitinib and achieved completed response, partial remission, or stable disease within 3 months after first dose of gefitinib. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors. Signed and dated informed consent before the start of specific protocol procedures. Allergic to icotinib. Gefitinib excepted, experience of Antitumor Monoclonal Antibody or small molecular compounds therapy such as erlotinib or Cetuximab. Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>